$CYAB

CYABRA, INC. (CYAB): Entry into a Material Definitive Agreement

CYABRA, INC. (CYAB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 7 ea029760001ex10-1.htm FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 9, 2026, between Cyabra, Inc., a Delaware corporation (the “ Company ”), and each purchaser

Original reporting
Published Jul 10, 2026, 8:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 10, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$CYAB
Neutral
medium confidence
Mentioned
$CYAB
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CYABNeutralMed
01

Why it matters

This type of disclosure typically corresponds to a private placement or similar financing. The key trading question is whether the terms imply meaningful dilution or warrant overhang versus a manageable capital need.

02

Market read

A new financing agreement can change the stock’s risk profile immediately, especially if pricing and warrant coverage are unfavorable.

03

What to watch

Traders should verify the final transaction size, subscription amount, conversion/warrant terms, and any resale-registration or lock-up provisions, which are not included in the excerpt.

Relevance 6/10Novelty 6/10Timing: Filed after-hours on 2026-07-10, ahead of the next trading session.

Background

The filing is an SEC Form 8-K (Item 1.01 and Item 3.02) describing entry into a material definitive agreement and unregistered sales of equity securities via a securities purchase agreement dated July 9, 2026.

Company-level read

Ticker impact

$CYABNeutralMedium confidence
Context

Cyabra, Inc. filed an 8-K stating it entered a material definitive agreement and a securities purchase agreement for unregistered equity sales.

Expected impact

Near-term downside bias is possible if the deal is dilutive or priced below market, but direction depends on the final purchase price, size, and warrant terms not shown in the excerpt.

Evidence & confidence

The article is an SEC 8-K for a securities purchase agreement, but the provided body excerpt is largely boilerplate definitions and does not include key deal economics (amount, price, discount, warrant coverage).

Market effects

Limited sector read-through; this is company-specific capital-raise mechanics rather than an industry-wide catalyst.

No clear regional spillover indicated by the excerpt.

No global macro or cross-border transaction details provided.

Counterpoint

If the financing is small, priced at a premium, or structured with limited dilution, the market reaction could be muted or even positive.

Key entities

  • Cyabra, Inc.

    Subject of the 8-K, entering a securities purchase agreement and disclosing unregistered equity sales.

  • Securities Purchase Agreement (Exhibit 10.1)

    Defines the transaction framework for issuance and sale of securities to purchasers under Regulation D and/or Section 4(a)(2).

Related articles

$CYABMedAI 8/10

Cyabra Announces Pricing of $6.0 Million Private Placement Priced At a Premium to the Market Price with New and Existing Institutional Investors, Management, and Board Members

Cyabra, Inc. (Nasdaq: CYAB) priced a $6.0 million private placement to sell 13,818,770 shares plus Series A and Series B warrants at $0.435 per share. Series A warrants exercise at $0.50 and expire five years; Series B exercise at $0.45 and expire 12 months, both subject to stockholder approval. Preferred shares will convert to common or equivalents, pending approval.

$ITWMed

Illinois Tool Works Authorizes $6 Bln Buyback

Illinois Tool Works (ITW) said its board authorized a new share repurchase program of up to $6 billion. The board also approved a 7% increase in its regular annual cash dividend to $6.88 per share, effective with the Q4 dividend of $1.72 payable Oct. 9, 2026. ITW closed at $296.66 on Friday.

$JNJMed

Money talcs: Why J&J offered $5.5bn to end cancer cases

Johnson & Johnson is offering $5.5 billion to settle most of more than 70,000 pending talc-related cancer lawsuits, according to the company. Claims allege ovarian cancer or mesothelioma linked to asbestos-contaminated talc. J&J denies wrongdoing and says cases lack merit. Prior orders include $966m (LA) and $1.5bn (Baltimore), with appeals planned.

$AAPLMed

Trump Tariff Refunds Just Topped $100 Billion, and These Companies Are Receiving Some of the Largest Checks

The U.S. Supreme Court invalidated Trump IEEPA tariffs, leaving the administration to refund about $166 billion. By Aug. 4, refunds exceeded $100 billion. Apple received $2.19 billion, Amazon $600 million, and others including Walmart ($2.4B), Ford ($1.3B), GM ($500M), and Costco (~$2B) are expected to receive large checks. New Section 301 tariffs may affect prices.

$MTZMed

Is MasTec’s Debt Raise and Upgraded Guidance Altering The Investment Case For MasTec (MTZ)?

MasTec (MTZ) completed a $647.76 million fixed-rate senior unsecured notes offering with a 5.85% coupon due Sept. 30, 2036. The company reported Q2 2026 sales of $4,373.55 million and net income of $130.12 million, and raised full-year 2026 revenue guidance to $18.2 billion and GAAP net income to $539 million, citing balance-sheet flexibility and governance updates.